208 related articles for article (PubMed ID: 19402172)
1. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Quinn JA; Desjardins A; Weingart J; Brem H; Dolan ME; Delaney SM; Vredenburgh J; Rich J; Friedman AH; Reardon DA; Sampson JH; Pegg AE; Moschel RC; Birch R; McLendon RE; Provenzale JM; Gururangan S; Dancey JE; Maxwell J; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2005 Oct; 23(28):7178-87. PubMed ID: 16192602
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
J Clin Oncol; 2009 Mar; 27(8):1262-7. PubMed ID: 19204199
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Broniscer A; Gururangan S; MacDonald TJ; Goldman S; Packer RJ; Stewart CF; Wallace D; Danks MK; Friedman HS; Poussaint TY; Kun LE; Boyett JM; Gajjar A
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6712-8. PubMed ID: 18006772
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
11. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
Cai W; Maldonado NV; Cui W; Harutyunyan N; Ji L; Sposto R; Reynolds CP; Keshelava N
Br J Cancer; 2010 Oct; 103(9):1369-79. PubMed ID: 20924375
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Desjardins A; Reardon DA; Peters KB; Threatt S; Coan AD; Herndon JE; Friedman AH; Friedman HS; Vredenburgh JJ
J Neurooncol; 2011 Dec; 105(3):601-6. PubMed ID: 21735117
[TBL] [Abstract][Full Text] [Related]
18. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
